Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies (NASDAQ: AKTS) announced the successful rollout of design updates to its XBAW® RF filters, aiming to remove patented features claimed by Qorvo. These updates respond to the legal verdict in Qorvo, Inc. vs. Akoustis Technologies, Inc., and have been incorporated into new and existing products since Fall 2022. Despite the jury’s verdict, Akoustis asserts that the design changes do not affect the performance or reliability of its products. The company is prepared for any potential injunctions and plans to continue marketing its product portfolio effectively.
Akoustis Technologies, Inc. reported third-quarter results with a 7% increase in revenue quarter-over-quarter, along with a 13% growth in filter-related revenue. The company anticipates breakeven operating cash flow in the next nine months due to cost-saving initiatives. Akoustis continues to secure design wins in various markets like Wi-Fi, 5G Infrastructure, Automotive, and Defense, projecting robust customer activity and revenue growth.
Akoustis Technologies, Inc. will webcast its Q3FY24 results on May 13 at 8:00 am ET. The company, known for its BAW high-band RF filters, maintains momentum with robust demand, an expanding sales pipeline, and new design wins in target markets like Wi-Fi, 5G Infrastructure, Automotive, and Defense.
Akoustis Technologies, Inc. announced the integration of four high-performance patented XBAW® filters into two new platforms with a Tier-1 Network Infrastructure customer. The filters will be used in Wi-Fi 7 enterprise and home gateway solutions, with production ramp scheduled throughout 2024. Akoustis continues to secure design wins in various target markets, showcasing robust demand for its products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.